Neogen Chemicals Limited announces a new order win

Fund Utilization Verdict

Neogen Chemicals has fully utilized the entire Rs 161 Crore raised through its previous preferential issue, leaving an exact unutilized balance of Nil (Rs 0) as of the Q1 FY27 monitoring report ^[1].

This complete deployment of equity capital indicates that the initial funding phase for the company's lithium-ion battery materials expansion is concluded ^[1]. However, because the Scheduled Commercial Operation Dates (SCODs) for the core Dahej and Pakhajan projects have been revised to late FY27 and early FY28 ^[2], the zero-balance status of this preferential issue means Neogen is now entirely reliant on debt, internal accruals, and subsidiary-level capital raises to fund the remaining capital expenditure and working capital gap ^[2].

---

Tracking Evidence: Fund Deployment & Project Timelines

1. Preferential Issue Utilization Status

• Total Funds Raised: Rs 161 Crore via preferential allotment to promoter group entity Cadamba Solutions ^[1].
• Unutilized Balance: Nil ^[1].
• Deployment Breakdown: Fully deployed across investments in wholly-owned subsidiaries (primarily Neogen Ionics), working capital requirements, and general corporate purposes ^[1].
• Audit Verification: Certified by statutory auditors M/s Chandabhoy & Jassoobhoy on July 23, 2026, and reviewed by the Audit Committee on July 24, 2026, confirming "No Deviation" ^[1].

2. Alignment with Commissioning Timelines

The complete deployment of these funds aligns with a critical transition phase where several facilities are moving from mechanical completion to trial runs and commercial production:

---

Institutional Implications

1. Funding Gap and Capital Structure Strain

With the Rs 161 Crore equity buffer fully exhausted ^[1], Neogen's leverage profile is under pressure. As of March 31, 2026, outstanding qualified borrowings stood at Rs 321.52 Crore ^[2]. To bridge the remaining capex for the Rs 1,795 Crore lithium battery materials roadmap ^[4], the company has had to initiate secondary funding structures. This is highlighted by Neogen Ionics approving a Rs 100.11 Crore rights issue in April 2026 for its step-down subsidiary, Neogen Morita New Material, to fund the salt business acquisition and ongoing CAPEX/OPEX ^[5].

2. Execution and Commercialization Risk

While the mechanical assembly of the Pakhajan electrolyte plant is complete ^[6], the revision of the official SCODs to March 31, 2027 (Dahej), and June 30, 2027 (Pakhajan), indicates that full commercial scaling is back-ended ^[2]. The immediate revenue generation is highly dependent on the September 2026 commissioning of the 2,000 MT Dahej electrolyte plant ^[3] and the Q3 FY27 commissioning of the 500 MT intermediate facility ^[4].

3. Customer Qualification and Revenue Visibility

The complete utilization of funds has successfully established the physical infrastructure required for customer site audits. Neogen has already been qualified by one domestic gigafactory (sole supplier, expanding from 1 GWh to 5 GWh) ^[4]. A second domestic gigafactory is scheduled to begin pilot production in Q2 FY27 ^[4]. Furthermore, three U.S.-based electrolyte makers have completed site audits for Neogen's non-FEOC compliant LiPF6 platform ^[4].

---

Material Gaps and Uncertainties

• Lender Approvals for SCOD: The revised SCODs of March 31, 2027, and June 30, 2027, remain subject to formal lender approvals ^[2]. Any delay in securing these approvals could impact debt covenant compliance.
• Morita JV Capital Infusion: While Morita Chemicals was scheduled to infuse USD 20 million of equity into the Joint Venture by Q1 FY27 ^[4], the final confirmation of this receipt has not been disclosed in the Q1 FY27 fund utilization report.

The proposed ₹600 crore Qualified Institutional Placement (QIP) represents a significant equity infusion, equivalent to approximately 73.5% of the company's FY26 consolidated net worth and 45.1% of its total consolidated debt. This fundraising signals a strategic pivot toward equity-led capital structure management to support ongoing expansion, contrasting with the debt-funded growth trajectory observed in recent periods.

Financial Comparison

The following table compares the proposed QIP size against the company's latest reported consolidated financial position as of FY26:

Strategic Shift in Capital Allocation

The proposed QIP indicates a shift in capital allocation strategy, moving from a reliance on debt to a more balanced approach that prioritizes equity to fund growth and manage leverage.

• Deleveraging and Balance Sheet Strength: With consolidated debt rising from Rs 393.53 crore in FY24 to Rs 1,329.9 crore in FY26 ^[22], the company has historically utilized debt to fuel its asset expansion. An equity infusion of this magnitude would provide substantial liquidity to fund capital expenditure without further increasing the interest burden, effectively moderating the debt-to-equity ratio.
• Recent Funding Precedent: The company recently demonstrated a preference for equity-based funding with a Rs 161 crore preferential issue in April 2026 ^[23]. This capital was fully utilized by June 30, 2026, for strategic purposes, including Rs 100 crore for capital expenditure on the Pakhanjan project and Rs 61 crore for working capital and debt adjustment ^[24]. The proposed QIP appears to be a continuation of this strategy, scaling up the equity component to support larger project requirements.
• Capital Allocation Focus: The shift suggests that management is prioritizing the funding of large-scale projects—such as the Pakhanjan project—through equity to maintain financial flexibility. By utilizing equity for both capex and debt adjustment, the company is actively managing its leverage profile while maintaining its growth momentum.

Material Caveats

• Proposed Nature: The QIP size is currently proposed; the final amount and timing remain subject to market conditions and regulatory approvals.
• Reporting Basis: All comparisons are based on FY26 consolidated figures ^[22]. Any significant changes in debt or equity positions since the close of FY26 are not reflected in these metrics.